Merck (MRK) Reports Election of Dr. Stephen Mayo to Board

Go back to Merck (MRK) Reports Election of Dr. Stephen Mayo to Board

Merck (MRK) Announces Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients with R/R Classical Hodgkin Lymphoma

February 1, 2021 6:37 AM EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of an expanded label for KEYTRUDA, Mercks anti-PD-1 therapy. The opinion is recommending KEYTRUDA as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a... More

Merck (MRK) Reports Results from Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab (Yervoy)

February 1, 2021 6:30 AM EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the Phase 3 KEYNOTE-598 study evaluating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with ipilimumab (Yervoy®) compared with KEYTRUDA monotherapy as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1 (tumor proportion score [TPS] 50%). Results of the study showed that the addition of ipilimumab to KEYTRUDA did not improve overall survival (OS) or progression-free survival (PFS) but added toxicity compared with KEYTRUDA monotherapy in these... More